Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $29.00 Consensus Target Price from Analysts

Key Points

• Astria Therapeutics, Inc. has received an average rating of "Buy" from seven analysts, with five recommending a buy and two a strong buy, aiming for a 12-month target price of $29.00.
• Institutional investors hold 98.98% of Astria Therapeutics' stock, with Deutsche Bank AG increasing its holdings by 54.3% in the latest quarter.
• The company's recent quarterly earnings report showed a loss of ($0.58) earnings per share, missing estimates by ($0.10), as analysts predict a projected loss of -1.65 EPS for the current fiscal year.

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have received an average recommendation of "Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $29.00.

Several brokerages have recently commented on ATXS. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Friday, June 13th. Cantor Fitzgerald restated an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a research note on Wednesday, May 14th.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS traded up $0.27 on Friday, hitting $6.83. 146,845 shares of the company's stock were exchanged, compared to its average volume of 364,534. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92. The stock has a market capitalization of $385.13 million, a price-to-earnings ratio of -3.66 and a beta of 0.48. The business's 50 day simple moving average is $5.84 and its two-hundred day simple moving average is $5.79.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Equities analysts forecast that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fcpm Iii Services B.V. purchased a new position in shares of Astria Therapeutics in the 4th quarter valued at approximately $25,680,000. ADAR1 Capital Management LLC raised its position in shares of Astria Therapeutics by 605.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after purchasing an additional 550,706 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Astria Therapeutics by 4.5% in the 4th quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company's stock valued at $37,369,000 after purchasing an additional 180,000 shares during the last quarter. Nuveen LLC purchased a new position in shares of Astria Therapeutics in the 1st quarter valued at approximately $553,000. Finally, Jane Street Group LLC raised its position in shares of Astria Therapeutics by 317.3% in the 1st quarter. Jane Street Group LLC now owns 108,898 shares of the biotechnology company's stock valued at $582,000 after purchasing an additional 82,805 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.